A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Some people with pancreatic ductal cancer (PDAC) have a protein called Claudin 18.2 (CLDN18.2) in their tumor. ASP2138 is thought to work by binding to CLDN18.2 and a protein on a type of immune cell called a T-cell. The T-cell "tells" the immune system to attack the tumor. This study is for people with resectable PDAC. Resectable means that the tumor can be removed by surgery. In this study, adults with resectable PDAC will receive an ASP2138 injection just below the skin (subcutaneous) 2 weeks before surgery. After surgery, they will be given standard chemotherapy treatments chosen by their study doctor. These include mFOLFIRINOX, gemcitabine with nab-paclitaxel, or gemcitabine with capecitabine. People will receive chemotherapy treatment for up to 6 months, or until their cancer gets worse, they cannot tolerate the chemotherapy, or they or their study doctor thinks they should stop chemotherapy. People will have a final clinic visit about a month after finishing chemotherapy for health checks.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza raka trzustki (adenokarcinoma), który można usunąć operacyjnie
- •Dodatni wynik testu na białko Claudin 18.2 w guzie
- •Wcześniej nie leczony nowotwór (bez wcześniejszych terapii)
- •Zdolność do przejścia operacji i chemioterapii
- •Przy problemach sercowych: wymagane badanie funkcji serca
- •Kobiety: nie mogą być w ciąży; muszą stosować antykoncepcję przez co najmniej 6 miesięcy po leczeniu
- •Kobiety: nie mogą karmić piersią przez całe badanie i 6 miesięcy po
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Massachusetts General Hospital
Boston, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Duke University Medical Center - Duke Cancer Center
Durham, United States
Trial contact
Astellas Pharma Global Development, Inc.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.